Corvus Pharmaceuticals Inc (CRVS) concluded trading on Thursday at a closing price of $3.35, with 4.1 million shares of worth about $13.74 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -62.86% during that period and on May 08, 2025 the price saw a gain of about 4.69%. Currently the company’s common shares owned by public are about 67.90M shares, out of which, 46.66M shares are available for trading.
Stock saw a price change of -4.83% in past 5 days and over the past one month there was a price change of 18.79%. Year-to-date (YTD), CRVS shares are showing a performance of -37.38% which increased to 75.39% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.75 but also hit the highest price of $10.00 during that period. The average intraday trading volume for Corvus Pharmaceuticals Inc shares is 760.14K. The stock is currently trading -0.39% below its 20-day simple moving average (SMA20), while that difference is down -8.62% for SMA50 and it goes to -36.10% lower than SMA200.
Corvus Pharmaceuticals Inc (NASDAQ: CRVS) currently have 67.90M outstanding shares and institutions hold larger chunk of about 34.20% of that.
The stock has a current market capitalization of $228.25M and its 3Y-monthly beta is at 0.57. It has posted earnings per share of -$0.97 in the same period. It has Quick Ratio of 1.54 while making debt-to-equity ratio of 0.03. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CRVS, volatility over the week remained 6.23% while standing at 6.89% over the month.
Analysts are in expectations that Corvus Pharmaceuticals Inc (CRVS) stock would likely to be making an EPS of -0.12 in the current quarter, while forecast for next quarter EPS is -0.11 and it is -0.55 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.13 which is -0.1 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.12 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 53.76% while it is estimated to decrease by -30.04% in next year. EPS is likely to grow at an annualized rate of 16.06% for next 5-years, compared to annual growth of 8.47% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on January 02, 2025 offering a Buy rating for the stock and assigned a target price of $11 to it. Coverage by Oppenheimer stated Corvus Pharmaceuticals Inc (CRVS) stock as an Outperform in their note to investors on August 18, 2023, suggesting a price target of $7 for the stock. On December 01, 2021, Jefferies Resumed their recommendations, while on May 27, 2021, Cantor Fitzgerald Initiated their ratings for the stock with a price target of $10. Stock get a Neutral rating from Mizuho on February 10, 2021.
